175 related articles for article (PubMed ID: 29410730)
1. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract][Full Text] [Related]
2. NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.
Manandhar S; Choi BH; Jung KA; Ryoo IG; Song M; Kang SJ; Choi HG; Kim JA; Park PH; Kwak MK
Free Radic Biol Med; 2012 May; 52(9):1773-85. PubMed ID: 22387177
[TBL] [Abstract][Full Text] [Related]
3. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Sui H; Shi C; Yan Z; Li H
Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641
[TBL] [Abstract][Full Text] [Related]
4. NRF2 Regulates HER2 and HER3 Signaling Pathway to Modulate Sensitivity to Targeted Immunotherapies.
Khalil HS; Langdon SP; Kankia IH; Bown J; Deeni YY
Oxid Med Cell Longev; 2016; 2016():4148791. PubMed ID: 26770651
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
6. A novel mechanism of action of HER2 targeted immunotherapy is explained by inhibition of NRF2 function in ovarian cancer cells.
Khalil HS; Langdon SP; Goltsov A; Soininen T; Harrison DJ; Bown J; Deeni YY
Oncotarget; 2016 Nov; 7(46):75874-75901. PubMed ID: 27713148
[TBL] [Abstract][Full Text] [Related]
7. Multidrug resistance-associated protein 1 mediates 15-deoxy-Δ(12,14)-prostaglandin J2-induced expression of glutamate cysteine ligase expression via Nrf2 signaling in human breast cancer cells.
Song NY; Kim DH; Kim EH; Na HK; Kim NJ; Suh YG; Surh YJ
Chem Res Toxicol; 2011 Aug; 24(8):1231-41. PubMed ID: 21728338
[TBL] [Abstract][Full Text] [Related]
8. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.
Puvanenthiran S; Essapen S; Seddon AM; Modjtahedi H
Int J Oncol; 2016 Nov; 49(5):1825-1838. PubMed ID: 27599579
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
[TBL] [Abstract][Full Text] [Related]
10. Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS.
Zhang R; Qiao H; Chen S; Chen X; Dou K; Wei L; Zhang J
Cancer Biol Ther; 2016 Sep; 17(9):925-34. PubMed ID: 27416292
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
[TBL] [Abstract][Full Text] [Related]
12. Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway.
Shim GS; Manandhar S; Shin DH; Kim TH; Kwak MK
Free Radic Biol Med; 2009 Dec; 47(11):1619-31. PubMed ID: 19751820
[TBL] [Abstract][Full Text] [Related]
13. Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors.
Kankia IH; Paramasivan P; Elcombe M; Langdon SP; Deeni YY
Explor Target Antitumor Ther; 2021; 2(2):187-203. PubMed ID: 36046141
[TBL] [Abstract][Full Text] [Related]
14. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
15. Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.
Formisano L; D'Amato V; Servetto A; Brillante S; Raimondo L; Di Mauro C; Marciano R; Orsini RC; Cosconati S; Randazzo A; Parsons SJ; Montuori N; Veneziani BM; De Placido S; Rosa R; Bianco R
Oncotarget; 2015 Sep; 6(28):26090-103. PubMed ID: 26325669
[TBL] [Abstract][Full Text] [Related]
16. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with erlotinib and pertuzumab against human tumor xenografts is superior to monotherapy.
Friess T; Scheuer W; Hasmann M
Clin Cancer Res; 2005 Jul; 11(14):5300-9. PubMed ID: 16033849
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
19. Rexinoid inhibits Nrf2-mediated transcription through retinoid X receptor alpha.
Wu J; Wang H; Tang X
Biochem Biophys Res Commun; 2014 Sep; 452(3):554-9. PubMed ID: 25172665
[TBL] [Abstract][Full Text] [Related]
20. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Suda K; Tomizawa K; Fujii M; Murakami H; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
J Thorac Oncol; 2011 Jul; 6(7):1152-61. PubMed ID: 21597390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
